HC Wainwright Forecasts Strong Price Appreciation for Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its price objective lifted by stock analysts at HC Wainwright from $85.00 to $100.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 43.70% from the company’s current price.

A number of other analysts have also issued reports on ARWR. Piper Sandler restated an “overweight” rating and set a $110.00 target price (up previously from $100.00) on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, January 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, October 8th. Bank of America lifted their price objective on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Morgan Stanley raised their price target on Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 7th. Finally, The Goldman Sachs Group upped their price objective on shares of Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the company a “neutral” rating in a research note on Wednesday, January 7th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $81.67.

Arrowhead Pharmaceuticals Price Performance

Arrowhead Pharmaceuticals stock opened at $69.59 on Wednesday. The stock has a market capitalization of $9.46 billion, a P/E ratio of -869.77 and a beta of 1.21. Arrowhead Pharmaceuticals has a 12-month low of $9.57 and a 12-month high of $76.76. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.86 and a quick ratio of 4.86. The firm’s 50-day moving average is $61.90 and its two-hundred day moving average is $39.60.

Insider Buying and Selling

In other news, insider James C. Hamilton sold 40,164 shares of the company’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $63.11, for a total value of $2,534,750.04. Following the completion of the transaction, the insider directly owned 171,958 shares in the company, valued at approximately $10,852,269.38. This represents a 18.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael S. Perry sold 16,250 shares of the stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $61.03, for a total value of $991,737.50. Following the transaction, the director owned 115,240 shares of the company’s stock, valued at approximately $7,033,097.20. This trade represents a 12.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 510,836 shares of company stock valued at $33,603,060. Insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Arrowhead Pharmaceuticals by 3.3% in the third quarter. Vanguard Group Inc. now owns 16,035,870 shares of the biotechnology company’s stock worth $553,077,000 after purchasing an additional 510,798 shares during the period. Avoro Capital Advisors LLC boosted its holdings in shares of Arrowhead Pharmaceuticals by 2.8% in the 3rd quarter. Avoro Capital Advisors LLC now owns 10,900,000 shares of the biotechnology company’s stock valued at $375,941,000 after buying an additional 300,000 shares during the period. Geode Capital Management LLC grew its position in shares of Arrowhead Pharmaceuticals by 1.0% during the 2nd quarter. Geode Capital Management LLC now owns 2,978,505 shares of the biotechnology company’s stock valued at $47,067,000 after buying an additional 28,193 shares during the last quarter. Marshall Wace LLP raised its stake in Arrowhead Pharmaceuticals by 3,507.8% during the second quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock worth $34,065,000 after acquiring an additional 2,096,238 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in Arrowhead Pharmaceuticals by 3,142.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company’s stock worth $71,797,000 after acquiring an additional 2,017,489 shares during the last quarter. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.